logo

BIAF

bioAffinity·NASDAQ
--
--(--)
--
--(--)
0.57 / 10
Underperform

Analysis concludes challenging fundamental quality (0.6/10). Favorable components: Net profit attributable to parent company shareholders / Net profit (%) and Cash-UP, though challenges appear in Net income-Revenue and Cash-MV. Investment recommendation: prudent.

Fundamental(0.57)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-2.46
Score3/3
Weight-60.11%
1M Return7.09%
ROA (%)
Value-130.37
Score0/3
Weight27.16%
1M Return-7.78%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight9.12%
1M Return-1.71%
Net income-Revenue
Value-0.17
Score1/3
Weight12.88%
1M Return-2.55%
Cash-UP
Value-0.06
Score2/3
Weight22.24%
1M Return-4.86%
Annualized net profit margin on total assets (%)
Value-173.82
Score0/3
Weight27.16%
1M Return-7.78%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight10.29%
1M Return-1.95%
Asset-MV
Value-0.50
Score0/3
Weight17.23%
1M Return-3.57%
Cash-MV
Value-0.07
Score1/3
Weight24.44%
1M Return-5.64%
Net profit / Total profit (%)
Value100.35
Score2/3
Weight9.58%
1M Return-1.71%
Is BIAF fundamentally strong?
  • BIAF scores 0.57/10 on fundamentals and holds a Premium valuation at present. Backed by its -204.66% ROE, -217.50% net margin, -0.21 P/E ratio, 0.35 P/B ratio, and 16.08% earnings growth, these metrics solidify its Underperform investment rating.